Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002346791 | SCV002640730 | likely pathogenic | Cardiovascular phenotype | 2016-09-09 | criteria provided, single submitter | clinical testing | The c.532+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 4 of the CASQ2 gene. This alteration has been reported in a homozygous state in two siblings with features of catecholaminergic polymorphic ventricular tachycardia (CPVT) (Postma AV et al. Circ. Res., 2002 Oct;91:e21-6). In addition, this variant has been detected in conjunction with another alteration in CASQ2 in a patient with CPVT (Delio M et al. PLoS ONE. 2015;10(7):e0133742). This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. However, loss of function of CASQ2 has not been clearly established as a mechanism of disease. As such, this alteration is classified as likely pathogenic. |
| Fulgent Genetics, |
RCV005002829 | SCV005632038 | pathogenic | Catecholaminergic polymorphic ventricular tachycardia 2 | 2024-01-05 | criteria provided, single submitter | clinical testing |